Case Western Reserve University

Cleveland, Ohio
Professor of Radiology, Biomedical Engineering and Pathology, Case Western Reserve University

Research

Diagnostics and therapy together in one agent is called theranostics. Dr. Basilion’s theranostic approach to treating cancer utilizes a novel compound or probe developed in his lab. With the probe, clinicians first visualize the precise location of prostate cancer cells, followed by light-activation of the probe to kill only prostate cancer cells. Current prostate cancer treatments include surgical removal or radiation of the prostate, however these treatments lead to unwanted side effects of erectile dysfunction, incontinence and bowel urgency. Dr. Basilion sought to create a therapy which would effectively treat prostate cancer without causing these debilitating side effects.

With NFCR funding beginning in 2005, Dr. Basilion created the novel probe to bind prostate specific membrane antigen (PSMA) — a protein found on prostate cancer cells, allowing clinicians to identify the precise location of cancer. When light is shown on the probe bound to PMSA, the probe becomes activated and causes cellular stress, killing only prostate cancer cells. PSMA is also found in new blood vessels of all solid tumors, allowing Dr. Basilion’s theranostic approach to potentially enhance outcomes of image-guided surgery and light treatment for patients with breast, prostate, colorectal, pancreas, brain and liver tumors.

Years of NFCR support to Dr. Basilion’s laboratory efforts have led to promising experimental imaging technology now being commercialized through the AIM-HI Translational Research Initiative. To learn more, click here.

Bio

James P. Basilion, Ph.D., studied biochemistry at the University of Pennsylvania in 1984 and attended graduate school at the University of Texas Health Science Center. He then completed his postdoctoral fellowship at the National Institutes of Health and, during this time, he began a series of studies with investigators at the Center for Molecular Imaging Research at Massachusetts General Hospital.

In 1996, Dr. Basilion worked at a small genomics and anti-cancer biotech company and, in 1999, he joined the faculty of Harvard Medical School and Massachusetts General Hospital-Center for Molecular Imaging Research. He was later recruited at the Case Western Reserve University Schools of Medicine and Engineering and is currently a professor in both the Departments of Radiology and Biomedical Engineering.

Dr. Basilion served as Director of the NFCR Center for Molecular Imaging from 2005 to 2017. Additionally, he serves as an external advisory board member for the Pacific Ovarian Cancer Research Consortium and Fred Hutchinson Cancer Center, and was a standing member on the MEDI Study Section for the National Institutes of Health. Dr. Basilion has held several offices in the Society for Molecular Imaging (SMI), and was instrumental in the merger to form the World Molecular Imaging Society (WMIS), where he served as treasurer.

Dr. Basilion provides reviews for several academic journals and holds editorial board positions for molecular imaging-centric journals. He has also founded Akrotome Imaging, Inc., a company devoted to the translation of molecular imaging technologies.

Related Content

The World’s First Oncolytic Virus Drug was Launched to Treat Malignant Brain Tumor GBM

Glioblastoma multiforme (GBM) is the most aggressive malignant brain tumor in adults, with a median survival of only about ten months. Unlike low-grade gliomas (grades I and II), which grow slowly, high-grade gliomas (grades III and IV) grow much faster and can spread to other parts of the brain, resulting in a patient’s death. GBM is the highest grade brain tumor (grade IV) with a very poor prognosis. The standard treatment for GBM includes surgery, radiation, and chemotherapy. However, these limited treatment approaches cannot control the tumor progress, and the rate of brain tumor recurrence is high, resulting in low overall survival (OS) in most patients.   Oncolytic Virus Therapy  Oncolytic virus therapy represents a new promising cancer immunotherapy approach that utilizes genetically modified viruses to infect and kill cancer cells. The viruses are modified to selectively infect and lyse cancer cells through genetic engineering processes while leaving normal cells unharmed. The genetic modification of the viruses also grants them the ability to produce immune-boosting molecules or initiate anti-cancer immunity through multiple mechanisms of the patient’s own immune system.  The First Oncolytic Virus Therapy for GBM  Recently, the world’s first oncolytic virus-based immunotherapy (Teserpaturev) was approved in Japan. Teserpaturev offers a new option for treating GBM and brings new hope to thousands of patients suffering from this malignant brain tumor.  Teserpaturev is a genetically engineered herpes simplex virus type 1 (HSV-1). The uniqueness of this new oncolytic virus-based drug is that it not only has strong killing power to brain tumor cells that the virus entered into, but it is also able to kill the tumor cells that have spread to other parts of the brain. This process happens by inducing systemic antitumor immunity of a patient’s own immune system.  In June 2021, Teserpaturev received a conditional and time-limited marketing approval in Japan to treat malignant glioma based on a Japanese phase 2 clinical trial in patients with GBM. The clinical trial results showed that 92% of patients who received Teserpaturev immunotherapy treatment were still alive after one year. This percent is considerably higher than the typical 15% one-year survival rate in this group of patients receiving standard late-stage brain tumor treatments.  Bottom Line Because Teserpaturev is currently under conditional and time-limited marketing approval in Japan, this novel immunotherapy for GBM is only available at specified hospitals in Japan. We hope international multi-center clinical trials on this innovative drug can take place in the near future. Hopefully, the novel therapy can be made available to GBM patients around the world.  Stay up-to-date with the latest information on new drug development. Receive our monthly e-newsletter and blogs featuring stories of inspiration, support resources, cancer prevention tips, and more; sign up here.  Additional Reads You May Also Enjoy: Treating Brain Cancer: What You Need to Know New Brain Scan Technology Can Improve Tumor Removal GBM AGILE – Changing the Way We Fight Brain Cancer References Daiichi Sankyo introduces Delytact in Japan to treat malignant glioma. com, November 2, 2021.  http://www.pharmabiz.com/NewsDetails.aspx?aid=143694&sid=2 First launch for Daiichi Sankyo’s oncolytic virus Delytact in Japan. Pharmaphorum, November 1, 2021.  https://pharmaphorum.com/news/first-launch-for-daiichi-sankyos-oncolytic-virus-delytact-in-japan/

Life Happens Quickly: Aly’s Story

As we grow older, we learn to understand that life happens quickly. Aly Newel learned just how quickly things could happen when she was screened for, diagnosed with, and received breast cancer treatment, all within 22 days. After losing her mother to breast cancer, Aly devotedly underwent her mammograms as recommended since turning 30 years old. In early 2016, she suddenly realized that she had missed her annual appointment by nearly six months. She quickly made an appointment, not thinking too much about the lapse as everything felt normal.  “My general practitioner told me that the test had detected abnormal cells in my left breast and that she was referring me to a surgeon,” Aly shared. “It wasn’t more than a couple of days before I was with the breast surgeon in absolute shock at how quickly this had happened. With everything that happened with my mom, I was scared.” Aly soon received the biopsy results that quickly filled her with dread as she learned she had breast cancer. Luckily, the ductal carcinoma in-situ was in the early stages and completely treatable.  “I was stunned,” Aly reflected. “How can he have just told me that I have breast cancer, yet it is curable? Honestly, it took me a while to get my head around that.” Before she could fully wrap her head around the news, Aly had a hook wire insertion and lumpectomy.  “These operations sound really scary, but they aren’t at all,” Aly said. “The surgeon came to see me after the operation and told me that everything had gone really well and that the cancer was gone.” Aly felt amazing – pain-free and thrilled to be rid of the nasty disease. She had zero pain and only a little scar on her left breast for which to remember the whirlwind experience. With just a single dose of radiotherapy, she closed this scary yet short chapter.  “I would like to share my story because as a mother of two daughters, I feel that it’s really important to promote early detection by encouraging women to become familiar with the regular feel of their breasts and participate in the screening programs that they are eligible for,” Aly stated. “I also think it’s important for people to realize that being diagnosed with breast cancer doesn’t necessarily have a bad outcome if it’s found early.” Life happens quickly, and sometimes it is easy to forget the small steps that make a big difference – like scheduling regular mammograms. Luckily, the National Foundation for Cancer Research (NFCR) has you covered. Follow NFCR on social media or check out our Cancer-Fighting Lifestyle Tips to keep you and your loved ones safe.  Additional Reads You May Enjoy: Let’s talk about Mammograms with Dr. Alexia Matheson Don’t Delay: Skipping One Mammogram Can Significantly Increase Risk of Death from Breast Cancer Mastectomy and Breast Reconstruction: What Breast Cancer Patients Should Know   Stay connected with the cancer community! Receive NFCR’s monthly e-newsletter and blogs featuring stories of inspiration, support resources, cancer prevention tips, and more. Sign up here.

Don’t Delay: Skipping One Mammogram Can Significantly Increase Risk of Death from Breast Cancer

One mammogram every two years doesn’t sound so bad – but what happens if a woman skips one? A recent study warns that missing just one mammogram before being diagnosed with cancer significantly increases a woman’s probability of dying from the disease.  The Importance of Mammograms Mammograms allow medical professionals to examine an x-ray of the breast tissue and look for any abnormalities or hints of cancer that other methods may not be able to detect. Having regularly scheduled mammograms presents an opportunity for early diagnosis, which significantly increases the ability to administer successful treatment. As signs and symptoms are often difficult to observe at early stages, mammograms have been the gold standard used for cancer detection and may reduce mortality by up to 40%. Because of this, the United States Preventative Services Task Force recommends that women aged 50-74 undergo a mammography every two years. Alarming Study Results In this ground-breaking study, a research team led by Stephen W. Duffy and Laszlo Tabar analyzed data from nearly 550,000 women with access to mammograms between 1992 and 2016. This data was divided into two groups – women who attended the two of the most recent mammograms before being diagnosed with breast cancer and those who did not.  The team discovered that the group who did not attend the two most recent mammograms before their diagnosis were more likely to have died within ten years of being diagnosed. The significant findings showed that 50% more of these group members had died than those who attended both most recent appointments. Overall, women who attended only one of the two breast cancer screenings had 29% higher mortality than those who attended both. While the research team anticipated a higher mortality rate among women who missed even one mammogram before their diagnosis, the disparity was astounding. As researchers unveil more evidence to highlight the importance of mammograms, however, medical professionals continue to identify a decrease in the number of women who undertake regular screenings. Tragically, the COVID-19 pandemic has also caused a significant decline in the number of women attending their regular mammograms.  What Next? Duffy, Laszlo, and their team hope their recent findings will inspire women to keep up-to-date with their mammogram appointments and plan to continue further prognostic research into the mechanisms of this effect. The team will explore to what extent regular attendance improves the prognosis of interval cancers and screen-detected cancers.  While the world eagerly awaits the following report, women must continue adhering to the current mammogram recommendations. Those with questions regarding their personal situation and recommendations should speak to their general practitioner.  For more information regarding breast cancer, please visit NFCR’s breast cancer page.  Note: The third Friday in October we recognize National Mammography Day. This year it will be celebrated on October 15, 2021. Please take this opportunity to schedule your mammogram or share important information with loved ones. Additional Reads You May Enjoy: Let’s talk about Mammograms with Dr. Alexia Matheson National Mammography Day 5 Ways You Can Show Support for Breast Cancer Patients Stay connected with the cancer community! Receive NFCR’s monthly e-newsletter and blogs featuring stories of inspiration, support resources, cancer prevention tips, and more. Sign up here.